Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03719768 · ClinicalTrials.gov registry record · Phase 1
Avelumab With Radiotherapy in Patients With Leptomeningeal Disease
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03719768 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 16 participants.
The verdict
NCT03719768, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study is to find a safe dose of the combination of Avelumab and Whole Brain Radiotherapy (WBRT) in patients with Leptomeningeal Disease.
Interventions
- DRUG Avelumab
- RADIATION Whole Brain Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-06-10 |
| Est. Completion | 2024-08-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03719768
The ClinicalTrials.gov registry entry for NCT03719768 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Avelumab is the first listed.
NCT03719768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03719768 about?
NCT03719768 is a clinical study titled "Avelumab With Radiotherapy in Patients With Leptomeningeal Disease". This study is to find a safe dose of the combination of Avelumab and Whole Brain Radiotherapy (WBRT) in patients with Leptomeningeal Disease.
What is the current status of trial NCT03719768?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2019-06-10. Estimated completion is 2024-08-21.
What interventions are being tested in trial NCT03719768?
The interventions under investigation include: Avelumab (DRUG), Whole Brain Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT03719768?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.